Perfluorohexyloctane Ophthalmic Solution for Dry Eye

Perfluorohexyloctane ophthalmic solution is the first prescription eye drop approved in the United States that contains no water at all. Sold under the brand name MIEBO, it works by physically slowing tear evaporation rather than adding moisture or suppressing inflammation, which makes it a genuinely different kind of dry eye treatment from anything that came before it. The compound itself is a semifluorinated alkane, a clear, odorless liquid that spreads across the surface of the eye and mimics the protective oil layer that healthy tear films rely on. Its approval was built on two large phase 3 trials, a year-long safety extension, and growing real-world data that together paint a picture worth understanding in some detail.

How It Actually Works

Most dry eye drops are aqueous, meaning they are essentially water-based solutions that temporarily supplement the watery part of your tears. Perfluorohexyloctane takes a completely different approach. Your tear film has multiple layers, and the outermost one is a thin oil layer produced by tiny glands in your eyelids called meibomian glands. When that oil layer is deficient or unstable, tears evaporate too quickly off the surface of the eye, leaving the cornea exposed and irritated. This evaporative mechanism is the most common driver of dry eye disease.

Perfluorohexyloctane spreads across the tear film and acts as a substitute for that failing oil layer. In laboratory testing, applying it over saline reduced the rate of evaporation by about 80%, strongly suggesting it forms a functional barrier against moisture loss.¹ Separate in vitro work confirmed that the compound significantly inhibits evaporation, supporting the idea that it can stand in for the native lipid layer when meibomian glands aren’t doing their job.² Beyond just sitting on top of the tear film, the compound may also help reorganize and stabilize whatever lipid layer is already there, improving its function rather than merely replacing it.

Because the drop contains no water and no preservatives, it avoids some of the problems associated with traditional artificial tears. Many preserved drops can irritate the ocular surface over time, and water-based formulations can actually wash away the very oils they’re meant to supplement. Perfluorohexyloctane sidesteps both issues. Its refractive index is close to that of water, and each drop is small, roughly 10 microliters, so it doesn’t blur your vision the way thicker gel drops can.³

The Trials That Led to Approval

The FDA approval rested primarily on two phase 3 randomized controlled trials, called GOBI and MOJAVE. Both enrolled adults with dry eye disease linked to meibomian gland dysfunction and compared perfluorohexyloctane (dosed four times daily) against a hypotonic saline control over eight weeks. The two primary endpoints in each trial were corneal fluorescein staining, which is a clinical measure of damage to the surface of the eye, and a patient-reported dryness score on a visual analog scale.

In the GOBI trial, perfluorohexyloctane outperformed saline on both measures at week 8, with a treatment difference of about 1.0 point on the staining scale and roughly 7.6 points on the dryness scale.⁴ The MOJAVE trial showed a similar pattern with slightly larger separations: a treatment difference of about 1.2 points for staining and roughly 10.2 points for dryness, with differences emerging as early as week 2.⁵

When researchers pooled data from both trials, covering over 1,200 patients combined, the overall treatment difference was about 1.1 points for staining and 9.0 points for dryness, both highly statistically significant. The pooled analysis also confirmed that the benefit held across every subgroup examined.⁶ A separate randomized trial in Chinese patients with meibomian gland dysfunction found broadly consistent results, with meaningful improvements in both staining and dryness scores appearing within the first two weeks and persisting through the 57-day study period.⁷

To put those numbers in everyday terms: the staining score runs from 0 to 15, where higher means more corneal damage. A one-point improvement over placebo is clinically meaningful because it reflects real healing of the corneal surface. The dryness score runs from 0 to 100, and a roughly 9-point advantage over placebo translates to a noticeable reduction in the feeling of gritty, dry eyes that patients deal with throughout the day.

What Happened Over a Full Year

Eight-week trials are useful for proving a drug works, but dry eye disease is a chronic condition, so patients and clinicians naturally want to know whether the benefits hold up and whether problems emerge with extended use. The KALAHARI study addressed this by enrolling 208 patients who had completed the GOBI trial into a year-long, open-label extension where everyone received perfluorohexyloctane four times daily for 52 weeks.

Patients who had been on the active drug in GOBI maintained their improvements in both staining and dryness scores throughout the full year. Patients who had been on saline in the original trial and then switched to perfluorohexyloctane in KALAHARI showed improvements by week 4 that then persisted for the remaining 48 weeks of the study.⁸

On the safety side, about 14% of patients reported at least one eye-related adverse event during that year, and most were mild or moderate. The most common issues were vitreous detachment, allergic conjunctivitis, blurred vision, and increased tearing, each occurring in fewer than 2% of patients. Other safety measures, including visual acuity, eye pressure, and retinal exams, were unremarkable.⁹ That safety profile is reassuring for a drop you’re instilling four times a day, every day, long term.

Does Severity Matter

One practical question patients ask is whether perfluorohexyloctane works better for mild cases, severe cases, or roughly the same across the board. A post hoc analysis of pooled trial data broke patients into subgroups based on how bad their baseline staining, dryness, tear breakup time, and meibomian gland scores were, then checked whether the treatment effect varied.

Overall, patients treated with perfluorohexyloctane were roughly twice as likely to achieve a clinically meaningful improvement in corneal staining compared with saline. That benefit was generally consistent regardless of baseline severity, with no statistically significant interaction for most measures.¹⁰ There was one notable exception: for the dryness symptom response, patients with more severe baseline corneal staining appeared to benefit more than those with milder staining, a finding that reached statistical significance.¹¹ In other words, people with more damaged corneal surfaces may notice a bigger symptom improvement, though the drug helps across the spectrum.

This is worth knowing if you have mild dry eye and wonder whether a prescription drop is overkill. The data suggest the treatment still produces a measurable benefit even in milder cases, but the relative advantage is most dramatic when baseline damage is worse.

Using It With Contact Lenses

A common concern for dry eye patients who wear contact lenses is whether perfluorohexyloctane is compatible with their lenses. The prescribing information instructs patients to remove lenses before instilling the drop and wait at least 30 minutes before reinserting them. That may sound inconvenient, but a prospective study in 47 habitual lens wearers, including people using both daily disposable and reusable lenses across hydrogel and silicone hydrogel materials, found the approach was safe and effective.

At four weeks, there was no significant worsening of corneal staining, meeting the primary safety endpoint. Dry eye symptom scores improved significantly, with a mean drop of about 6 points on the staining scale.¹² The study was small, and the 30-minute wait is a real constraint for people who rely on lenses all day. But for contact lens wearers whose dry eye symptoms are otherwise poorly controlled, the data at least suggest this is a workable option.

How It Fits Among Other Dry Eye Treatments

The dry eye treatment landscape has historically been split between artificial tears for temporary relief, and prescription anti-inflammatory or immunomodulatory agents like cyclosporine and lifitegrast that target the underlying inflammation driving the disease. Perfluorohexyloctane doesn’t fall neatly into either camp. It is a prescription product, but it is not an anti-inflammatory. It’s a physical intervention that targets tear evaporation directly, which makes it the first topical therapy designed specifically for the evaporative subtype of dry eye.¹³

This distinction matters because many patients with meibomian gland dysfunction have been using treatments that address inflammation or supplement the watery layer of tears, neither of which directly tackles their core problem. Perfluorohexyloctane fills a gap. That said, dry eye is frequently a mixed condition: the same patient may have both evaporative and aqueous-deficient components. For mixed disease, combining perfluorohexyloctane with other therapies could make sense, though head-to-head comparison trials against existing prescription drops haven’t been published. Clinicians are largely working from mechanistic logic and early clinical experience when they prescribe it alongside other agents.

The “Is It a PFAS Chemical” Question

Perfluorohexyloctane’s name alone raises eyebrows. It contains a perfluorinated segment, which inevitably triggers the question: is this a PFAS, one of the “forever chemicals” associated with environmental contamination and health concerns? The answer requires some nuance.

PFAS (per- and polyfluoroalkyl substances) are a huge family of chemicals defined by carbon-fluorine bonds. In the broadest chemical sense, perfluorohexyloctane has structural overlap: part of the molecule is a fully fluorinated carbon chain. But the compound is a semifluorinated alkane, meaning only half the molecule carries fluorine atoms, and it lacks the ionic head group (like a carboxylate or sulfonate) found in the legacy PFAS compounds most associated with toxicity and environmental persistence, such as PFOA and PFOS.

A recent study in human liver cells, however, found that perfluorohexyloctane can be metabolized into at least one biotransformation product: perfluorohexyloctanoic acid, which is a carboxylic acid derivative that structurally resembles certain fluorotelomer carboxylic acids.¹⁴ This finding is preliminary, coming from in vitro cell exposures rather than from patients using the eye drop at clinical doses. The concentration at which this metabolite appears and whether it reaches meaningful systemic levels through topical ocular use are open questions. Still, the discovery that the body can convert the compound into something that looks more like a traditional PFAS metabolite is the kind of finding that warrants attention as long-term surveillance data accumulate.

For patients weighing practical risks right now, the relevant context is that the doses reaching systemic circulation from an eye drop are extremely small compared with environmental PFAS exposures through drinking water or food. But the science on this specific question is genuinely early, and people with particular sensitivity to PFAS-related concerns should be aware of it.

Why the Drop Itself Feels Different

Patients switching from traditional artificial tears often notice that perfluorohexyloctane feels different in the eye. It is not a viscous gel, and it is not a watery solution. Because it is an anhydrous liquid with a very low surface tension, it spreads rapidly and thinly across the ocular surface. The drop size is small, about 10 microliters, compared with the 30-50 microliters typical of most eye drops. That smaller volume means less overflow onto the cheeks and less of the transient blurring that thicker formulations cause.

The flip side is that some patients initially find the sensation unfamiliar, almost like instilling nothing at all. Others report mild stinging or a slight warming feeling for a few seconds. Neither reaction is uncommon with any new eye drop, and the clinical trials showed that most adverse events were mild and infrequent. The four-times-daily dosing schedule is consistent with how the drop is thought to work: it forms a temporary barrier that gradually dissipates between doses, so regular reapplication maintains the protective effect throughout the day.

Potential as a Drug Delivery Vehicle

Beyond its standalone use, semifluorinated alkanes like perfluorohexyloctane have been studied as vehicles for delivering other drugs to the eye. Poorly water-soluble medications, including cyclosporine, struggle with corneal penetration when formulated in traditional aqueous eye drops. Research has shown that dissolving cyclosporine in semifluorinated alkanes dramatically improved corneal penetration compared with a standard commercial formulation, with at least an eightfold increase in local drug exposure.¹⁵

This line of research suggests that perfluorohexyloctane or related compounds could eventually serve double duty: reducing evaporation while simultaneously delivering anti-inflammatory drugs to the ocular surface more effectively than current formulations allow. No combination product is on the market yet, but the drug delivery platform is under active investigation, and if it pans out, it could reshape how ophthalmologists treat patients who need both physical and pharmacological intervention for their dry eye disease.

The Tear Film Thickness Connection

An earlier mechanistic study explored whether perfluorohexyloctane eye drops actually change measurable tear film thickness in patients with mild to moderate dry eye. The rationale was straightforward: if the drop reduces evaporation, the remaining tear film should be thicker because less of it is being lost to the air. That study used optical coherence tomography to track tear film changes, providing a direct physical measurement of the proposed mechanism.¹⁶ While the large phase 3 trials measured clinical outcomes like staining and symptom scores, this kind of mechanistic work helps confirm that the drug is doing what the theory predicts at a physical level, not just producing improvements through some indirect route.

Understanding tear film dynamics also helps explain why perfluorohexyloctane may complement warm compress therapy and lid hygiene, the traditional first-line treatments for meibomian gland dysfunction. Those approaches aim to unblock glands and improve the natural lipid layer over time. Perfluorohexyloctane provides an immediate synthetic substitute for that lipid function, buying time while gland health is being addressed. For patients whose glands are severely atrophied and unlikely to recover full function, the drop may serve as a long-term physical prosthesis for a lipid layer that simply cannot be restored.